Welcome to our dedicated page for Journey Medical SEC filings (Ticker: DERM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Journey Medical Corporation (DERM) SEC filings page on Stock Titan provides access to the company’s public regulatory documents as filed with the U.S. Securities and Exchange Commission. Journey Medical is a commercial-stage pharmaceutical company focused on selling and marketing FDA-approved prescription pharmaceutical products for dermatological conditions, with its common stock listed on The Nasdaq Capital Market under the symbol DERM and registered pursuant to Section 12(b) of the Securities Exchange Act of 1934.
Through its SEC filings, investors can review Journey Medical’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe its dermatology-focused business, portfolio of eight branded FDA-approved prescription drugs, risk factors, and financial statements. Current reports on Form 8-K provide updates on material events, including quarterly financial results, amendments to credit agreements, at-the-market equity sales programs, changes to the company’s certificate of incorporation, index inclusion announcements, and disclosures related to the commercialization and pharmacy benefit coverage of Emrosi (DFD-29) for inflammatory lesions of rosacea in adults.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand topics such as Journey Medical’s revenue composition, term loan arrangements, equity issuance programs, governance changes, and other significant disclosures. Real-time updates from the EDGAR system ensure that new 8-Ks, 10-Qs, and 10-Ks are reflected promptly, while access to exhibits and related materials allows for deeper review when needed.
In addition, users can monitor forms that disclose capital markets and corporate actions referenced in Journey Medical’s filings. By combining original SEC documents with AI-generated explanations, this page is intended to make Journey Medical’s regulatory history and ongoing reporting more accessible to investors, analysts, and others researching DERM.
Journey Medical Corp reported significant insider activity as President & CEO Claude Maraoui received new equity compensation awards on June 17, 2025. The transactions include:
- 49,277 restricted stock units granted at $0, vesting in three equal annual installments from January 2026 to January 2028
- 82,915 stock options granted with a strike price of $6.31, also vesting over three years from January 2026 to January 2028
Following these transactions, Maraoui beneficially owns 2,397,590 shares directly, including previously granted restricted stock units. As both a Director and CEO, this equity compensation aligns with long-term shareholder interests through a three-year vesting schedule. The grants were made under the company's 2015 Stock Plan, demonstrating continued executive retention efforts.